EMJ GOLD

A federal court has come down hard on Robert F. Kennedy Jr.’s CDC advisory panel appointments – blocking them over concerns around expertise and process, and freezing key vaccine recommendations in the process. Learn more about the case: hubs.la/Q04cX26Q0

Is Eli Lilly hedging its bets outside of the obesity market? The company plans to buy Kelonia Therapeutics for up to $7bn, gaining access to an experimental multiple myeloma therapy that reprogrammes patients’ immune cells inside the body. Learn more: hubs.la/Q04cShn60

Would you trust a drug discovered by an OpenAI model? The company has announced its own platform for early-stage drug discovery, with early adopters including companies such as Amgen, Moderna, the Allen Institute and Thermo Fisher Scientific. 🔗: hubs.la/Q04cxC9W0

The #obesitymarket rivalry continues between Novo Nordisk and Eli Lilly. A new real-world analysis by @_nference has found tirzepatide delivers more weight loss than semaglutide – but it may also cost patients more muscle. Learn more about the study: hubs.la/Q04cvj4J0

In this new column, Dr Henar Hevia, @JNJInnovMed, explores how real-world evidence and better decision-making can improve outcomes, personalise treatment and close the gap between innovation and care. Read now: hubs.la/Q04cv8dL0

More from #WIREDHealth: Kathleen Fisher, CEO, ARIA, shared a story about failure. A synthetic blood programme didn’t work as intended. But the same technology showed potential elsewhere. It eventually led to Moderna’s mRNA platform. Sign up for more: hubs.la/Q04clYmB0

The team are at #WIREDHealth to capture the key insights for pharma. Top moment so far: Lord Vallance calls on UK funds to invest in life sciences, noting only Canadian funds, and pensioners, are currently reaping the rewards. Sign up for full round up: hubs.la/Q04cjW230

Amazon Web Services has launched a new artificial intelligence platform for drug discovery, which, crucially, researchers can use without writing code for the first time. Early adopters include @MSKCancerCenter. Learn more: hubs.la/Q04c6Y6g0 #AIinHealthcare

Update: Novo Nordisk join forces with with OpenAI. “This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare," said President and CEO Mike Doustdar. Read more: hubs.la/Q04bWpY90

One in three men in England are dying before 75. A new £6.3m fund set up by Men’s Health Community Fund, the People’s Health Trust and the UK government aims to change that, by meeting men where they actually seek help: in their communities. Learn more: hubs.la/Q04byJt50

A new federal pilot allows Medicare organisations to discuss and furnish hemp-derived CBD products - without FDA approval and without going through standard regulatory process. 🔗: hubs.la/Q04bp7Ly0

Novo Nordisk has launched a 7.2 mg semaglutide injection in the US - nearly three times the previous highest available dose. FDA-approved in March, the new dose showed average weight loss of approximately 21% at 72 weeks in the phase 3 STEP UP trial. 🔗hubs.la/Q04bc0l70

Cardiovascular disease costs the world $680bn a year. A new OHE report suggests up to $480bn of that could be avoided. The key? Early detection and management of moderately elevated LDL-C at scale. Read more: hubs.la/Q04b1zbX0

Great science means nothing if patients can't trust, understand or use it. VML's Health Futures 2026 report warns that rising misinformation is eroding patient confidence faster than innovation can rebuild it. Read more: hubs.la/Q04b0fwr0 #WorldHealthDay

Big news in obesity care: Eli Lilly’s once-daily oral GLP-1, orforglipron, has received FDA approval. In clinical trials, patients achieved ~12% weight loss at the highest dose, alongside improvements in key cardiovascular risk factors. Read more: hubs.la/Q049qY_90

Supply chains and clinical trials are coming under pressure as Middle East instability escalates. Only 22% of pharma companies were actively preparing for disruption, according to Argon & Co. Meanwhile, 4,300 trials have been impacted, says Phesi. 🔗: hubs.la/Q049hvYn0

Month in pharma: March 2026, explained 👇 From Takeda's restructure to fuel its late-stage pipeline, to space-based drug manufacturing gaining traction in the UK, March showed the industry is never a boring place to be. Discover the full round up: hubs.ly/Q049f_hF0

Is FDA scrutiny of biologics marketing increasing? The CBER has ended a period of relative dormancy with a rare quartet of untitled letters to Iovance, BMS, Novartis and Gilead’s Kite Pharma. Learn more: hubs.la/Q0492NtK0

Lilly and Insilico strike $2.75bn AI R&D alliance Eli Lilly and Company has entered a major strategic collaboration with Insilico Medicine, marking a high-stakes expansion of generative AI in its pipeline. Learn more:hubs.la/Q048VjWZ0

Endometriosis treatment has long meant hormones, side effects and trade-offs. What if the next wave targets inflammation instead? A new phase 2 trial from Gesynta Pharma is underway, investigating a non-hormonal treatment for the condition. Read now: hubs.la/Q048Q_b50